ID: ALA2326828

Max Phase: Preclinical

Molecular Formula: C18H21N7O5

Molecular Weight: 415.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(/C=N/Nc2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)cc1

Standard InChI:  InChI=1S/C18H21N7O5/c1-29-10-4-2-9(3-5-10)6-21-24-18-22-15(19)12-16(23-18)25(8-20-12)17-14(28)13(27)11(7-26)30-17/h2-6,8,11,13-14,17,26-28H,7H2,1H3,(H3,19,22,23,24)/b21-6+/t11-,13-,14-,17-/m1/s1

Standard InChI Key:  UKEASMXMANFUQZ-DXALFEDPSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 415.41

Molecular Weight (Monoisotopic): 415.1604

AlogP: -0.53

#Rotatable Bonds: 6

Polar Surface Area: 173.16

Molecular Species: NEUTRAL

HBA: 12

HBD: 5

#RO5 Violations: 1

HBA (Lipinski): 12

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 11.84

CX Basic pKa: 4.70

CX LogP: 0.26

CX LogD: 0.24

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.26

Np Likeness Score: 0.07

References

1. Niiya K, Thompson RD, Silvia SK, Olsson RA..  (1992)  2-(N'-aralkylidenehydrazino)adenosines: potent and selective coronary vasodilators.,  35  (24): [PMID:1469688] [10.1021/jm00102a008]

2. El-Tayeb A, Gollos S..  (2013)  Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands.,  21  (2): [PMID:23245803] [10.1016/j.bmc.2012.11.021]

Source

Source(1):

• Scientific Literature